Ipilimumab biosimilar(Eden Biologics)

伊匹木单抗生物类似药（喜康生物）

Report date: 2024/07/01 15:37:50

Base Information

Drug NameIpilimumab biosimilar(Eden Biologics)

Drug Alias NameJHL-1152EB-1003

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors

TargetsCytotoxic T-Lymphocyte-Associated Antigen 4

Therapy Area/IndicationsMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesEden Biologics Inc

China Registration ClassN/A

Develop Information

Active CompaniesEden Biologics Inc

Inactive CompaniesN/A

Active IndicationsMelanoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A